Biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) said on Thursday that it has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its investigational AAV5 gene therapy, valoctocogene roxaparvovec, for adults with haemophilia A.
The FDA has accepted the BLA under its priority review and breakthrough therapy designation. This is the first marketing application accepted for a gene therapy product for any type of haemophilia in the United States.
Currently, no advisory committee meeting is planned to review the application, The Prescription Drug User Fee Act (PDUFA) action date is 21 August 2020.
The BLA is based on the company's Phase 3 interim analysis of study participants treated with investigational product manufactured by the to-be-commercialized process and three-year Phase 1/2 data. The gene therapy manufacturing facility is located in Novato, California and the facility is ready for inspection to support approval.
In addition, the FDA has accepted the company's Premarket Approval (PMA) application for an AAV5 total antibody assay intended as a companion diagnostic test for valoctocogene roxaparvovec. Approximately 80% of people with haemophilia A in the US do not have pre-existing immunity to AAV5 that would make them ineligible for AAV5-mediated gene therapy treatment.
People living with haemophilia A lack enough functioning Factor VIII protein to help their blood clot and are at risk of painful and/or potentially life-threatening bleeds from even modest injuries.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT